Key points are not available for this paper at this time.
This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.
Building similarity graph...
Analyzing shared references across papers
Loading...
Al B. Benson
Alan P. Venook
Lynette Cederquist
Journal of the National Comprehensive Cancer Network
The University of Texas MD Anderson Cancer Center
University of Alabama at Birmingham
St. Jude Children's Research Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Benson et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69da21ffb48bb130d4684291 — DOI: https://doi.org/10.6004/jnccn.2017.0036
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: